title: Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.
abstract: BACKGROUND
  malignant peritoneal mesothelioma (MPM) is a rare peritoneal mesothelial neoplasm. Ki67 and BCL2 are established prognostic markers in several cancers. High Ki67 expression indicates tumour progression, whilst similar expression of BCL2 retards tumour replication. Traditionally, prognosis in MPM is gauged with a single biomarker assessed separately in a dichotomous manner. Here, we examine prognosis with dual biomarkers incorporated in a model to predict survival.
  
  
  METHODS
  Forty two MPM archival patient tumours were screened for Ki67 and BCL2 by immunohistochemistry and evaluated using standard methods. Ki67 and BCL2 expression was incorporated into a prognostic model to develop Ki67-BCL2 index. Using this index, three hazard groups were identified (high, medium and low risk). Kaplan-Meier survival analysis was performed to assess the significance of these hazard groups in the various clinicopathological categories.
  
  
  RESULTS
  In all clinicopathological categories, high risk group showed poor prognosis compared to low risk group (p = < 0.001). Compared to medium risk, high risk group carried poor prognosis in all tumours, females, epitheloid tumours, peritoneal cancer index (PCI) < 20, ≥ 20, age at diagnosis (AAD) < 60, and ≥ 60 years. Independent of the Ki67-BCL2 index, male, sarcomatoid, PCI ≥ 20 and AAD ≥ 60 were poor prognostic factors. High risk group was an independent poor prognostic factor in all tumours, males, females and age < 60 years. The distribution of high risk: low risk group in male and female was 3: 2 and 2: 3, respectively, indicating a gender difference. Comparing hazard ratios generated by Ki67-BCL2 index to that of either Ki67 or BCL2, as a single prognostic biomarker, there was a reduction of HR values.
  
  
  CONCLUSIONS
  Ki67-BCL2 index seems to suggest a more sensitive method of predicting prognosis. However, the current model needs further evaluation in an independent large cohort sample.
authors: Department of Surgery, St. George Hospital, University of New South Wales Kogarah, NSW 2217, Australia.
authors: Krishna
authors: K
authors: Pillai
authors: Mohammad H
authors: MH
authors: Pourgholami
authors: Terence C
authors: TC
authors: Chua
authors: David L
authors: DL
authors: Morris
keywords: BCl2; Ki67; malignant peritoneal mesothelima; prognosis
references: Nat Clin Pract Oncol. 2008 Oct;5(10):588-99
references: 18695711
references: J Clin Oncol. 2005 Oct 1;23(28):7212-20
references: 16192605
references: Cancer. 2011 May 1;117(9):1855-63
references: 21509762
references: J Pathol. 2012 Jan;226(1):97-107
references: 21953021
references: J Transl Med. 2006 Apr 10;4:17
references: 16606461
references: Mod Pathol. 1998 Feb;11(2):155-68
references: 9504686
references: Cancer Res. 2009 Jun 1;69(11):4598-604
references: 19487281
references: J Clin Oncol. 1999 May;17(5):1474-81
references: 10334533
references: PLoS One. 2010 Nov 29;5(11):e14110
references: 21124760
references: Ann Med. 2009;41(5):371-9
references: 19191082
references: Virchows Arch. 1994;424(6):631-4
references: 8055157
references: Ann Surg Oncol. 2010 Jan;17(1):45-53
references: 19856030
references: PLoS One. 2012;7(5):e36856
references: 22590625
references: Mol Cancer Ther. 2009 Nov;8(11):3056-65
references: 19887552
references: Eur J Cardiothorac Surg. 2011 Aug;40(2):298-303
references: 21310625
references: J Natl Cancer Inst. 2008 Feb 6;100(3):207-12
references: 18230798
references: Cancer Res. 1994 Jul 15;54(14):3714-7
references: 8033089
references: J Pathol. 2010 Dec;222(4):388-99
references: 20922713
references: Int J Hyg Environ Health. 2005;208(3):201-10
references: 15971859
references: Ann Diagn Pathol. 2013 Feb;17(1):99-103
references: 22784439
references: Med Mol Morphol. 2010 Mar;43(1):53-9
references: 20340007
references: J Clin Oncol. 2005 Mar 10;23(8):1616-22
references: 15755967
references: Eur J Endocrinol. 2011 Jun;164(6):971-6
references: 21422198
references: J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
references: 21960707
references: Breast Cancer Res Treat. 2010 Apr;120(2):293-308
references: 20107892
references: J Natl Cancer Inst. 1993 Feb 3;85(3):200-6
references: 8423624
references: BMC Cancer. 2006 Aug 01;6:203
references: 16882345
references: Lancet. 2002 Jun 22;359(9324):2131-9
references: 12090977
references: Mod Pathol. 2010 Mar;23(3):470-9
references: 20081811
references: Breast Cancer Res Treat. 2012 Apr;132(3):895-915
references: 22048814
references: Cancer. 2002 Jan 15;94(2):378-85
references: 11905410
references: Cell Death Differ. 2006 Aug;13(8):1351-9
references: 16763616
references: Ann Surg Oncol. 2007 Jan;14(1):41-9
references: 17039392
references: Eur J Surg Oncol. 2012 Jun;38(6):503-8
references: 22281154
references: J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
references: 17228000
references: J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88
references: 20082099
references: Oncogene. 2002 Nov 7;21(51):7765-75
references: 12420213
references: Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):949-57
references: 15184251
references: Int J Clin Exp Pathol. 2011 Jun 20;4(5):444-53
references: 21738816
references: BMC Cancer. 2011 Nov 14;11:486
references: 22081974
references: BMC Cancer. 2008 May 29;8:153
references: 18510726
references: In Vivo. 2009 Mar-Apr;23(2):203-7
references: 19414404
references: Br J Surg. 2006 Dec;93(12):1536-42
references: 17048277
references: J Clin Oncol. 1988 Jan;6(1):147-53
references: 3335886
references: Blood. 2009 Sep 10;114(11):2273-9
references: 19597184
references: Crit Rev Oncol Hematol. 2005 Sep;55(3):231-40
references: 15979890
references: Urology. 2011 Apr;77(4):842-7
references: 21256565
references: Semin Oncol. 2003 Jun;30(3 Suppl 7):34-46
references: 12840799
references: J Clin Oncol. 2008 Dec 1;26(34):5569-75
references: 18981464
references: Surg Oncol. 2009 Dec;18(4):357-65
references: 19027288
references: Int J Cancer. 2012 Oct 1;131(7):E1109-19
references: 22418857
references: Int J Cancer. 1983 Jan 15;31(1):13-20
references: 6339421
references: Br J Cancer. 2009 Mar 24;100(6):888-93
references: 19293807
references: Cancer Res. 1992 Dec 15;52(24):6940-4
references: 1458483
references: Asian Pac J Cancer Prev. 2012;13(5):2229-34
references: 22901199
references: Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi
references: 14567020
references: Rom J Morphol Embryol. 2010;51(4):655-61
references: 21103622
references: MedGenMed. 2007 May 10;9(2):32
references: 17955087
references: Endocr Relat Cancer. 2004 Dec;11(4):643-58
references: 15613444
references: J Clin Oncol. 2001 Feb 15;19(4):1147-51
references: 11181680
references: Ann Oncol. 2010 Feb;21(2):348-353
references: 19635740
references: Nature. 1990 Nov 22;348(6299):334-6
references: 2250705
references: Br J Cancer. 2010 Aug 24;103(5):668-75
references: 20664598
references: Lancet. 2005 Jul 30-Aug 5;366(9483):397-408
references: 16054941
references: J Med Case Rep. 2011 Jan 26;5:36
references: 21269462
references: Ann Oncol. 2012 Jun;23(6):1494-8
references: 22056853